All of these ongoing trials use a genomic (NGS, FISH) or proteomic biomarker (IHC, immunostaining), it is unclear which of these modalities will fare as the most optimal biomarker for EGFR-positive gastric cancer; however, using some form of selection stratification is imperative in best identifying an inclusion biomarker in these patients. The gene discussed is EGFR; the disease is gastric cancer.